A gut probiotic cut kidney stone crystals in rats by lowering one bile acid

If you have had a calcium oxalate kidney stone, or you live with someone who has, you have probably wondered why stones keep coming back. A new study from Fudan University's Huashan Hospital points to an unexpected suspect: the gut. In rats, a probiotic bacterium cut crystal buildup in the kidneys, and the trail led through a single bile acid.

Key Takeaways

• In a rat model of calcium oxalate kidney stones, daily Clostridium butyricum markedly reduced kidney crystal deposits and injury, and the protection carried over through a fecal transplant.
• Stone patients in three human cohorts had less C. butyricum in their stool, and in two cohorts more of a bile acid called GHDCA. Those are associations, not proof of cause.
• This is animal work with six rats per group and no clinical trial. It does not show that a probiotic prevents stones in people.

Clostridium butyricum Cut Kidney Crystal Buildup in Rats

The study, published online in the Journal of Pharmaceutical Analysis by Zijian Zhou and colleagues, found that rats given the probiotic Clostridium butyricum (CB, a gut bacterium already used as a digestive probiotic) had markedly less calcium oxalate crystal deposition in their kidneys than untreated rats. The rats drank water with 1% ethylene glycol and 0.5% ammonium chloride for four weeks to induce crystals, and the treated group also received 1 billion CFU (colony-forming units, a count of living bacteria) of CB by gavage each day.

Micro-CT scans and tissue staining showed fewer crystals in the CB group. Those rats also had better blood markers of kidney function (blood urea nitrogen and serum creatinine), lower kidney levels of the inflammatory signals IL-1β and IL-6, and less oxidative stress in kidney tissue.

The team then followed the trail to a bile acid. Bile acids are digestive compounds made from cholesterol in the liver and reworked by gut bacteria. Of 39 bile acids measured, glycohyodeoxycholic acid (GHDCA) was the only one that changed consistently in stool, blood and kidney tissue: higher in the stone-model rats, lower when they got CB.

Calcium Oxalate Kidney Stones and the Gut Connection

Calcium oxalate stones are the most common type of kidney stone, and the authors note they have high incidence and recurrence rates. The usual explanations, such as supersaturated urine, oxidative stress and tubule injury, do not fully account for them, which the authors say leaves prevention options limited.

A growing body of work, reviewed in Nature Reviews Urology, ties gut microbes to stones. The authors point to earlier reports that Lactobacillus acidophilus can block crystal growth while Escherichia coli can promote it. Oxalobacter formigenes, a bacterium that breaks down oxalate, has also been studied, though the authors describe it as sensitive to antibiotics and unstable as a probiotic. The Kidney Stone Microbiome (KiSMi) study found the gut microbiota of stone formers differs from that of healthy controls, and its data were reused here as an independent check.

Human Stool Metagenomics Plus Rat Rescue Experiments

The study combined human stool sequencing with a chain of rat and cell experiments. In people, metagenomic sequencing (reading all the bacterial DNA in a stool sample) found less CB in stone patients than in healthy controls. It did so in a training cohort of 18 stool samples per group at Huashan Hospital, a testing cohort of 25 per group from Ruijin Hospital, and a public dataset of 40 patients and 30 controls. The ability of CB abundance to separate patients from controls was AUC 0.864 in training, 0.800 in testing and 0.708 in the public data (1.0 would be a perfect separation, 0.5 a coin flip).

In rats, 18 animals were split into control, stone-model and CB groups of six. To test whether the gut ecosystem mattered, the team cleared other rats' gut bacteria with antibiotics and gave them stool from CB-treated or untreated donors. Recipients of CB-donor stool showed less kidney injury and crystal deposition, so the benefit appears to depend on the gut microbiota.

For the mechanism, GHDCA made oxalate-induced damage worse in human (HK-2) and rat (NRK-52E) kidney cell lines, and it acted through the vitamin D receptor (VDR, a protein that senses vitamin D and, it turns out, some bile acids). Silencing VDR reduced the damage. Finally, CB-treated rats fed GHDCA in their diet lost their protection, and a VDR-blocking drug blunted the added damage.

What the C. butyricum Findings Could Mean for Stone Patients

For someone managing kidney stones, the honest reading is that this points to a mechanism worth studying, not a treatment to try. In the human samples, GHDCA was higher in the stool, blood and urine of stone patients. In the stool of patients, more GHDCA went with less CB (R = -0.587, P = 0.012, in the 18-per-group training cohort; R = -0.421 in the testing cohort). That fits the rat story but cannot show that one causes the other.

Nothing here supports buying a C. butyricum supplement to prevent stones. A systematic review of probiotic and synbiotic studies concluded that routine use of these products for kidney stone prevention cannot be recommended on current evidence. If you form stones and are curious about your gut, that is a conversation for your urologist or nephrologist, alongside the prevention advice you already have.

Small Groups, One Rat Model, and Unanswered Questions

The biggest limit is scale. Each rat group had six animals, all of one type (male Sprague-Dawley rats), tested with a single commercially sourced CB strain. The authors acknowledge they used only a rat model, did not directly analyze the composition of the crystals or stones, and relied on a VDR inhibitor and siRNA (a tool that switches off one gene) rather than gene knockouts.

The human data are modest too. The difference in overall gut composition between patients and controls was statistically detectable but weak (ANOSIM R = 0.043, P = 0.036), and the human work is a snapshot, so it cannot say whether low CB comes before stones or after.

There is also a real gap in the mechanism. In lab culture, CB metabolized primary bile acids but did not produce GHDCA, and butyrate levels in the rats did not change. The authors conclude that CB probably lowers GHDCA indirectly, through other gut bacteria or host factors. How it does so is not yet known.

Next Steps: Knockout Models, Larger Animals and VDR Signaling

The authors say their next steps are gene knockout experiments to test the VDR link more rigorously, studies in larger animals (they name pigs, dogs and cats) where recovered stones can be analyzed directly, and work on what VDR does downstream in stone formation. They describe the results as a "theoretical basis" for future probiotic or small-molecule therapies. The paper announces no clinical trial and gives no timeline.

Common Questions

Does Clostridium butyricum prevent kidney stones in people? Not shown. This study found less CB in patients' stool and protection in rats, but it did not test CB in people.

What is GHDCA? Glycohyodeoxycholic acid is a secondary bile acid, meaning gut bacteria help produce it. In this study it was higher in stone-model rats and in stone patients' stool, blood and urine, and it worsened oxalate damage in kidney cells.

How is this different from Oxalobacter formigenes? O. formigenes is best known for breaking down oxalate. This study traced a different route, a gut bile acid acting through the vitamin D receptor.

References

1. Zijian Zhou, Xuan Zhou, Jinfang Liu, et al. (2026). Clostridium butyricum attenuates calcium oxalate nephrolithiasis via gut microbiota and GHDCA-VDR axis. Journal of Pharmaceutical Analysis. https://doi.org/10.1016/j.jpha.2026.101799
2. Aaron W. Miller, Kristina L. Penniston, Kate Fitzpatrick, José Agudelo, Gregory Tasian, Dirk Lange (2022). Mechanisms of the intestinal and urinary microbiome in kidney stone disease. Nature Reviews Urology. https://doi.org/10.1038/s41585-022-00647-5
3. Maanya Bhardwaj, Abhinav Singhal, Gaurika Bhardwaj, Ivo Dukic (2025). Probiotic and Synbiotic Interventions Targeting Oxalate-Degrading Gut Bacteria for the Prevention of Kidney Stones: A Systematic Review. Cureus. https://doi.org/10.7759/cureus.98728